Utama › Astrositoma › Texas
Kajian klinikal Astrositoma di Texas
15 kajian untuk Astrositoma sedang mencari peserta di lokasi di Texas.
Bandar di Texas
Teks kajian rasmi (Bahasa Inggeris)
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
- M D Anderson Cancer Center, Houston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT03896568Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06047379A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Baylor Scott & White Research Institute, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT05765812Targeted Pediatric High-Grade Glioma Therapy
- Texas Children's Hospital, Houston
Mengambil pesertaKajian pemerhatian
12 Months – 39 Years · Semua jantina · Dikemas kini 8 Sep 2026 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 1
36 Months – 22 Years · Semua jantina · Dikemas kini 4 Sep 2026 · NCT03911388Study of Olutasidenib and Temozolomide in HGG
- Texas Children's Hospital, Houston
Mengambil pesertaFasa 2
Umur 12 hingga 39 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- University of Texas Health Mays Cancer Center, San Antonio
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT05303519Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Houston
- Research Site, San Antonio
Mengambil pesertaFasa 1/2
Umur 18 hingga 130 · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT05417594Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
- Excel Diagnostics & Nuclear Oncology Center, Houston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT07733674Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
- M D Anderson Cancer Center, Houston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Jul 2026 · NCT04623931Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Texas Children's Hospital, Houston
Mengambil pesertaFasa awal 1Sukarelawan sihat dialu-alukan
Umur 1 hingga 21 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Texas Children's Hospital, Houston
Mengambil pesertaFasa 2
12 Months – 39 Years · Semua jantina · Dikemas kini 29 Mei 2026 · NCT05843253HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- Houston Methodist Neurological Institute, Houston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Mac 2026 · NCT03596086HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
- Houston Methodist Neurological Institute, Houston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Mac 2026 · NCT03603405Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- UT MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Jun 2025 · NCT05879367Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.